Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
NASDAQ: SHPH · Real-Time Price · USD
0.853
-0.045 (-5.06%)
Nov 21, 2024, 1:08 PM EST - Market open
Company Description
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers.
It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .
The company is based in Gaithersburg, Maryland.
Shuttle Pharmaceuticals Holdings, Inc.
| Country | United States |
| Founded | 2012 |
| IPO Date | Aug 31, 2022 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Anatoly Dritschilo |
Contact Details
Address: 401 Professional Drive, Suite 260 Gaithersburg, Maryland 20879 United States | |
| Phone | (240) 403-4212 |
| Website | shuttlepharma.com |
Stock Details
| Ticker Symbol | SHPH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $8.13 |
| CIK Code | 0001757499 |
| CUSIP Number | 825693203 |
| ISIN Number | US8256932034 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Anatoly Dritschilo M.D. | Co-Founder, Chief Executive Officer and Chairman of the Board |
| Peter Dale Dritschilo M.B.A., M.D. | President and Chief Operating Officer |
| Dr. Milton Brown CSC, M.D., Ph.D. | Co-Founder and Director |
| Dr. Tyvin A. Rich M.D. | Chief Clinical Officer and Chief Medical Officer |
| Dr. Mira Jung Ph.D. | Co-Founder and Chief Scientific Officer for Biology |
| Gene Jung Esq. | General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 13, 2024 | 8-K | Current Report |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 1, 2024 | 8-K | Current Report |
| Oct 31, 2024 | 424B4 | Prospectus |
| Oct 29, 2024 | EFFECT | Notice of Effectiveness |
| Oct 29, 2024 | 8-K | Current Report |
| Oct 28, 2024 | 8-K | Current Report |
| Oct 28, 2024 | 8-K | Current Report |
| Oct 25, 2024 | 8-K | Current Report |
| Oct 25, 2024 | D | Notice of Exempt Offering of Securities |